Genetic and cellular basis of cerebral cavernous malformations: Implications for clinical management

Clinical Genetics

Volumn 83, Issue 1, 2013, Pages 7-14

  Bacigaluppi, S ^a   Retta, Sf ^b   Pileggi, S ^c   Fontanella, M ^d,e   Goitre, L ^b   Tassi, L ^f   La Camera, A ^c   Citterio, A ^c   Patrosso, Mc ^c   Tredici, G ^a   Penco, S ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

^f Department of Neuroscience   (Italy)

Author keywords

Cavernomas; Cavernous angioma; CCM genes; Genetics; Genetics of stroke; Guideline; Magnetic resonance imaging; Molecular mechanisms; Pathophysiology

Indexed keywords

FASUDIL; SORAFENIB;

CAVERNOUS HEMANGIOMA; CHROMOSOME 3Q; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; GENE EXPRESSION; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCIDENCE; MOLECULAR MECHANICS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

BRAIN; CENTRAL NERVOUS SYSTEM; CEREBRAL HEMORRHAGE; GENETIC COUNSELING; HEMANGIOMA, CAVERNOUS, CENTRAL NERVOUS SYSTEM; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS; SEIZURES;

MORUS (ANGIOSPERM);

EID: 84871230410     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2012.01892.x     Document Type: Review

References (91)

1. Victor M, Ropper AH, Adams RD. In: Victor M, Ropper AH, eds. Principles of neurology, 7th edn. New York, NY: McGraw-Hill, 2001.
2. Sirvente J, Enjolras O, Wassef M, Tournier-Lasserve E, Labauge P. Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations. J Eur Acad Dermatol Venereol 2009: 23: 1066-1072.
3. Labauge P, Krivosic V, Denier C, Tournier-Lasserve E, Gaudric A. Frequency of retinal cavernomas in 60 patients with familial cerebral cavernomas: a clinical and genetic study. Arch Ophthalmol 2006: 124: 885-886.
4. Otten P, Pizzolato GP, Rilliet B, Berney J. 131 cases of cavernous angioma (cavernomas) of the cns, discovered by retrospective analysis of 24, 535 autopsies. Neurochirurgie 1989: 35: 82-83, 128-131.
5. Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg 1991: 75: 709-714.
6. Raychaudhuri R, Batjer HH, Awad IA. Intracranial cavernous angioma: a practical review of clinical and biological aspects. Surg Neurol 2005: 63: 319-328. Discussion 328.
7. Labauge P, Denier C, Bergametti F, Tournier-Lasserve E. Genetics of cavernous angiomas. Lancet Neurol 2007: 6: 237-244.
8. Washington CW, McCoy KE, Zipfel GJ. Update on the natural history of cavernous malformations and factors predicting aggressive clinical presentation. Neurosurg Focus 2010: 29: E7.
9. Del Curling O Jr. Kelly DL Jr, Elster AD, Craven TE. An analysis of the natural history of cavernous angiomas. J Neurosurg 1991: 75: 702-708.
10. Kondziolka D, Lunsford LD, Kestle JR. The natural history of cerebral cavernous malformations. J Neurosurg 1995: 83: 820-824.
11. Rigamonti D, Drayer BP, Johnson PC, Hadley MN, Zabramski J, Spetzler RF. The mri appearance of cavernous malformations (angiomas). J Neurosurg 1987: 67: 518-524.
12. Lehnhardt FG, von Smekal U, Ruckriem B et al. Value of gradient-echo magnetic resonance imaging in the diagnosis of familial cerebral cavernous malformation. Arch Neurol 2005: 62: 653-658.
13. Zabramski JM, Wascher TM, Spetzler RF et al. The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg 1994: 80: 422-432.
14. Campbell PG, Jabbour P, Yadla S, Awad IA. Emerging clinical imaging techniques for cerebral cavernous malformations: a systematic review. Neurosurg Focus 2010: 29: E6.
15. Clatterbuck RE, Eberhart CG, Crain BJ, Rigamonti D. Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J Neurol Neurosurg Psychiatry 2001: 71: 188-192.
16. Cauley KA, Andrews T, Gonyea JV, Filippi CG. Magnetic resonance diffusion tensor imaging and tractography of intracranial cavernous malformations: preliminary observations and characterization of the hemosiderin rim. J Neurosurg 2010: 112: 814-823.
17. Tu J, Stoodley MA, Morgan MK, Storer KP. Ultrastructural characteristics of hemorrhagic, nonhemorrhagic, and recurrent cavernous malformations. J Neurosurg 2005: 103: 903-909.
18. Wong JH, Awad IA, Kim JH. Ultrastructural pathological features of cerebrovascular malformations: a preliminary report. Neurosurgery 2000: 46: 1454-1459.
19. Rigamonti D, Hadley MN, Drayer BP et al. Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med 1988: 319: 343-347.
20. Petersen TA, Morrison LA, Schrader RM, Hart BL. Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype. AJNR Am J Neuroradiol 2010: 31: 377-382.
21. Dubovsky J, Zabramski JM, Kurth J et al. A gene responsible for cavernous malformations of the brain maps to chromosome 7q. Hum Mol Genet 1995: 4: 453-458.
22. Gunel M, Awad IA, Anson J, Lifton RP. Mapping a gene causing cerebral cavernous malformation to 7q11.2-q21. Proc Natl Acad Sci U S A 1995: 92: 6620-6624.
23. Craig HD, Gunel M, Cepeda O et al. Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet 1998:7:1851-1858.
24. Sahoo T, Johnson EW, Thomas JW et al. Mutations in the gene encoding krit1, a krev-1/rap1a binding protein, cause cerebral cavernous malformations (ccm1). Hum Mol Genet 1999: 8: 2325-2333.
25. Laberge-le Couteulx S, Jung HH, Labauge P et al. Truncating mutations in ccm1, encoding krit1, cause hereditary cavernous angiomas. Nat Genet 1999: 23: 189-193.
26. Denier C, Goutagny S, Labauge P et al. Mutations within the mgc4607 gene cause cerebral cavernous malformations. Am J Hum Genet 2004: 74: 326-337.
27. Liquori CL, Berg MJ, Siegel AM et al. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet 2003: 73: 1459-1464.
28. Guclu B, Ozturk AK, Pricola KL et al. Mutations in apoptosis-related gene, pdcd10, cause cerebral cavernous malformation 3. Neurosurgery 2005: 57: 1008-1013.
29. Bergametti F, Denier C, Labauge P et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 2005: 76: 42-51.
30. Riant F, Bergametti F, Ayrignac X, Boulday G, Tournier-Lasserve E. Recent insights into cerebral cavernous malformations: the molecular genetics of ccm. FEBS J 2010: 277: 1070-1075.
31. Petit N, Blecon A, Denier C, Tournier-Lasserve E. Patterns of expression of the three cerebral cavernous malformation (ccm) genes during embryonic and postnatal brain development. Gene Expr Patterns 2006: 6: 495-503.
32. Verlaan DJ, Roussel J, Laurent SB, Elger CE, Siegel AM, Rouleau GA. Ccm3 mutations are uncommon in cerebral cavernous malformations. Neurology 2005: 65: 1982-1983.
33. Gianfrancesco F, Esposito T, Penco S et al. Zpld1 gene is disrupted in a patient with balanced translocation that exhibits cerebral cavernous malformations. Neuroscience 2008: 155: 345-349.
34. Serebriiskii I, Estojak J, Sonoda G, Testa JR, Golemis EA. Association of krev-1/rap1a with krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene 1997: 15: 1043-1049.
35. Glading A, Han J, Stockton RA, Ginsberg MH. Krit-1/ccm1 is a rap1 effector that regulates endothelial cell cell junctions. J Cell Biol 2007: 179: 247-254.
36. Zhang J, Clatterbuck RE, Rigamonti D, Chang DD, Dietz HC. Interaction between krit1 and icap1alpha infers perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation. Hum Mol Genet 2001: 10: 2953-2960.
37. Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA. Krit1 association with the integrin-binding protein icap-1: a new direction in the elucidation of cerebral cavernous malformations (ccm1) pathogenesis. Hum Mol Genet 2002: 11: 389-396.
38. Zawistowski JS, Stalheim L, Uhlik MT et al. Ccm1 and ccm2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet 2005: 14: 2521-2531.
39. Francalanci F, Avolio M, De Luca E et al. Structural and functional differences between krit1a and krit1b isoforms: a framework for understanding ccm pathogenesis. Exp Cell Res 2009: 315: 285-303.
40. Uhlik MT, Abell AN, Johnson NL et al. Rac-mekk3-mkk3 scaffolding for p38 mapk activation during hyperosmotic shock. Nat Cell Biol 2003: 5: 1104-1110.
41. Voss K, Stahl S, Schleider E et al. Ccm3 interacts with ccm2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics 2007: 8: 249-256.
42. Wang Y, Liu H, Zhang Y, Ma D. Cdna cloning and expression of an apoptosis-related gene, human tfar15 gene. Sci China C Life Sci 1999: 42: 323-329.
43. Plummer NW, Zawistowski JS, Marchuk DA. Genetics of cerebral cavernous malformations. Curr Neurol Neurosci Rep 2005: 5: 391-396.
44. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971: 68: 820-823.
45. Sure U, Butz N, Schlegel J et al. Endothelial proliferation, neoangiogenesis, and potential de novo generation of cerebrovascular malformations. J Neurosurg 2001: 94: 972-977.
46. Marchuk DA, Srinivasan S, Squire TL, Zawistowski JS. Vascular morphogenesis: tales of two syndromes. Hum Mol Genet 2003: 12 (Spec No. 1): R97-R112.
47. Beraud-Dufour S, Gautier R, Albiges-Rizo C, Chardin P, Faurobert E. Krit 1 interactions with microtubules and membranes are regulated by rap1 and integrin cytoplasmic domain associated protein-1. FEBS J 2007: 274: 5518-5532.
48. Hilder TL, Malone MH, Bencharit S et al. Proteomic identification of the cerebral cavernous malformation signaling complex. J Proteome Res 2007: 6: 4343-4355.
49. Gore AV, Lampugnani MG, Dye L, Dejana E, Weinstein BM. Combinatorial interaction between ccm pathway genes precipitates hemorrhagic stroke. Dis Model Mech 2008: 1: 275-281.
50. Chan AC, Li DY, Berg MJ, Whitehead KJ. Recent insights into cerebral cavernous malformations: animal models of ccm and the human phenotype. FEBS J 2010: 277: 1076-1083.
51. Patterson C. Torturing a blood vessel. Nat Med 2009: 15: 137-138.
52. Whitehead KJ, Chan AC, Navankasattusas S et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med 2009: 15: 177-184.
53. Kleaveland B, Zheng X, Liu JJ et al. Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. Nat Med 2009: 15: 169-176.
54. McDonald DA, Shenkar R, Shi C et al. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet 2011: 20: 211-222.
55. Yoruk B, Gillers BS, Chi NC, Scott IC. Ccm3 functions in a manner distinct from Ccm1 and Ccm2 in a zebrafish model of CCM vascular disease. Dev Biol 2012: 362: 121-131.
56. Chan AC, Drakos SG, Ruiz OE et al. Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice. J Clin Invest 2011: 121: 1871-1881.
57. Schleider E, Stahl S, Wüstehube J, Walter U, Fischer A, Felbor U. Evidence for anti-angiogenic and pro-survival functions of the cerebral cavernous malformation protein 3. Neurogenetics 2011: 12: 83-86.
58. Denier C, Labauge P, Bergametti F et al. Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol 2006: 60: 550-556.
59. Yadla S, Jabbour PM, Shenkar R, Shi C, Campbell PG, Awad IA. Cerebral cavernous malformations as a disease of vascular permeability: from bench to bedside with caution. Neurosurg Focus 2010: 29: E4.
60. Faurobert E. Recent insights into cerebral cavernous malformations. FEBS J 2010: 277: 1069.
61. Louvi A, Chen L, Two AM, Zhang H, Min W, Gunel M. Loss of cerebral cavernous malformation 3 (ccm3) in neuroglia leads to ccm and vascular pathology. Proc Natl Acad Sci U S A 2011: 108: 3737-3742.
62. Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (ccms): evidence for a two-hit mechanism of ccm pathogenesis. Hum Mol Genet 2009: 18: 919-930.
63. Gault J, Awad IA, Recksiek P et al. Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery 2009: 65: 138-144. Discussion 135-144.
64. Pagenstecher A, Stahl S, Sure U, Felbor U. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of ccm1, ccm2 or ccm3 in affected endothelial cells. Hum Mol Genet 2009: 18: 911-918.
65. Jung KH, Chu K, Jeong SW, Park HK, Bae HJ, Yoon BW. Cerebral cavernous malformations with dynamic and progressive course: correlation study with vascular endothelial growth factor. Arch Neurol 2003: 60: 1613-1618.
66. Chrissobolis S, Faraci FM. The role of oxidative stress and nadph oxidase in cerebrovascular disease. Trends Mol Med 2008: 14: 495-502.
67. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol 2011: 300: H1566-H1582.
68. Goitre L, Balzac F, Degani S et al. Krit1 regulates the homeostasis of intracellular reactive oxygen species. PLoS One 2010: 5: e11786.
69. Shi C, Shenkar R, Du H et al. Immune response in human cerebral cavernous malformations. Stroke 2009: 40: 1659-1665.
70. Chen Y, Pawlikowska L, Yao JS et al. Interleukin-6 involvement in brain arteriovenous malformations. Ann Neurol 2006: 59: 72-80.
71. Achrol AS, Pawlikowska L, McCulloch CE et al. Tumor necrosis factor-alpha-238g>a promoter polymorphism is associated with increased risk of new hemorrhage in the natural course of patients with brain arteriovenous malformations. Stroke 2006: 37: 231-234.
72. Fontanella M, Rainero I, Gallone S et al. Tumor necrosis factor-alpha gene and cerebral aneurysms. Neurosurgery 2007: 60: 668-672.
73. Fontanella M, Rainero I, Gallone S et al. Interleukin-1 cluster gene polymorphisms and aneurysmal subarachnoid hemorrhage. Neurosurgery 2010: 66: 1058-1062.
74. Fontanella M, Rubino E, Crobeddu E et al. Brain arteriovenous malformations are associated with interleukin-1 cluster gene polymorphisms. Neurosurgery 2012: 70: 12-17.
75. Basuroy S, Bhattacharya S, Leffler CW, Parfenova H. Nox4 nadph oxidase mediates oxidative stress and apoptosis caused by tnf-alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol 2009: 296: C422-C432.
76. Schouten JP, McElgunn CJ, Waaijer R et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002: 30: e57.
77. Penco S, Ratti R, Bianchi E et al. Molecular screening test in familial forms of cerebral cavernous malformation: the impact of the multiplex ligation-dependent probe amplification approach. J Neurosurg 2009: 110: 929-934.
78. Ohnesorg T, Turbitt E, White SJ. The many faces of mlpa. Methods Mol Biol 2011: 687: 193-205.
79. Muscarella LA, Guarnieri V, Coco M et al. Small deletion at the 7q21.2 locus in a ccm family detected by real-time quantitative pcr. J Biomed Biotechnol 2010: 2010. pii: 854737.
80. Denier C, Goutagny S, Labauge P et al. Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet. 2004: 74 (2): 326-337.
81. Liquori CL, Penco S, Gault J et al. Different spectra of genomic deletions within the CCM genes between Italian and American CCM patient cohorts. Neurogenetics 2008: 9: 25-31.
82. Lucas M, Costa AF, Montori M, Solano F, Zayas MD, Izquierdo G. Germline mutations in the CCM1 gene, encoding Krit1, cause cerebral cavernous malformations. Ann Neurol 2001: 49: 529-532.
83. Mosca L, Pileggi S, Avemaria F et al. De novo MGC4607 gene heterozygous missense variants in a child with multiple cerebral cavernous malformations. J Mol Neurosci. Epub 14 March 2012.
84. Stahl S, Gaetzner S, Voss K et al. Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. Hum Mutat 2008: 29: 709-717.
85. D'Angelo R, Marini V, Rinaldi C et al. Mutation analysis of ccm1, ccm2 and ccm3 genes in a cohort of italian patients with cerebral cavernous malformation. Brain Pathol 2011: 21: 215-224.
86. Faraci FM. Oxidative stress: the curse that underlies cerebral vascular dysfunction? Stroke 2005: 36: 186-188.
87. Adam O, Laufs U. Antioxidative effects of statins. Arch Toxicol 2008: 82: 885-892.
88. Kuhlmann CR, Gerigk M, Bender B, Closhen D, Lessmann V, Luhmann HJ. Fluvastatin prevents glutamate-induced blood-brain-barrier disruption in vitro. Life Sci 2008: 82: 1281-1287.
89. McDonald DA, Shi C, Shenkar R et al. Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke 2012: 43: 571-574.
90. Wüstehube J, Bartol A, Liebler SS et al. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci U S A 107: 12640-12645.
91. von der Brelie C, Schramm J. Cerebral cavernous malformations and intractable epilepsy: the limited usefulness of current literature. Acta Neurochir (Wien) 2011: 153: 249-259.